Naperville, IL -- (SBWIRE) -- 07/23/2013 -- Reportstack, provider of premium market research reports announces the addition of Albaconazole (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022 market report to its offering
Albaconazole (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022
Summary
The publisher has released its new PharmaPoint Drug Evaluation report, Albaconazole (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022. Dermatophytic onychomycosis (DO) is characterized as being a fungal infection of the nail. Infection can involve the nail unit (nail matrix, nail bed, or nail plate). DO isnt considered life-threatening, however can cause patients to experience discomfort, pain, and may cause physical and occupational limitations. DO patients can be identified as having thick or brittle nails along with discoloration (white and opaque). Physicians currently use direct microscopy and fungal culture tests to ensure correct diagnosis and treatment are achieved. Risk factors such as advanced age, pre-existing diabetes, or immunocompromised systems can increase the incidence of DO in patients. Current therapies consist of generics that offer substantial efficacy but sub-par safety profiles. A new wave of therapies is expected to offer topical options for patients who are unable to withstand existing generic options. These therapies are also expected to drive an increase in total drug treatment rates in the US market.
Albaconazole is a novel triazole antifungal that was originally developed by Palau Pharma in Barcelona, Spain, and was later licensed to Stiefel, the US based-dermatology company. Stiefel, which was acquired by GlaxoSmithKline (GSK), subsequently conducted a Phase IIb study testing multiple doses of albaconazole. Despite the successful results of the trial, albaconazole was returned to Palau Pharma when GSK decided to not pursue further development of the drug for the US market. Currently, Palau Pharma is actively in search of a development partner to test albaconazole in Phase III trials and bring it to market.
Scope
- Overview of Dermatophytic Onychomycosis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Albaconazole including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Albaconazole for the US from 2012 to 2022.
- Sales information covered for the US
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Dermatophytic Onychomycosis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Albaconazole performance
- Obtain sales forecast for Albaconazole from 2012 to 2022 in the US
To view the table of contents for this market research report please visit
http://www.reportstack.com/product/127719/albaconazole-dermatophytic-onychomycosis-forecast-and-market-analysis-to-2022.html
Contact:
Ana Viste
contactus@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604
###